Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Quaternary Ammonium Polyethylenimine Nanoparticles	NCIT_C88305	[A crosslinked nanoparticle formulation containing quaternary ammonium polyethylenimine (QA-PEI) with potential antibacterial activity. The cationic polymer PEI kills bacteria by rupturing their cell membranes without the development of resistance. Quaternary ammonium polyethylenimine nanoparticles can be incorporated into dental composite resins or silicon obturator prostheses and may prevent or delay bacterial growth.]
PARP1 Inhibitor PF-01367338	NCIT_C88306
Anti-EGFRvIII Immunotoxin MR1-1	NCIT_C88307	[A recombinant immunotoxin consisting of single-chain variable domain fragment antibody directed against the tumor-specific antigen EGFRvIII (MR1scFv) fused to domains II and III of the Pseudomonas exotoxin (PE38KDEL), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-EGFRvIII immunotoxin MR1-1 binds to EGFRvIII; upon internalization, the exotoxin portion inhibits protein synthesis, resulting in a reduction in tumor cell proliferation of EGFRvIII- expressing tumor cells. EGFRvIII, a type III in-frame deletion mutation of the epidermal growth factor receptor (EGFR) gene, is expressed by a variety of cancers, including glioblastoma multiforme, non-small lung carcinoma, and breast carcinoma. Compared to intact IgG antibodies, single-chain antibodies such as MR1scFv are smaller and may penetrate tumors better. Pseudomonas exotoxin PE38KDEL was modified to remove the natural cell binding domain.]
Plozalizumab	NCIT_C88308	[A humanized monoclonal antibody directed against the human chemokine receptor 2 (CCR2), with potential antiangiogenic, immunomodulating, antimetastatic, and antineoplastic activities. Plozalizumab binds to CCR2 and prevents binding of the endothelium-derived CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and so inhibition of angiogenesis, tumor cell migration, and tumor cell proliferation. In addition, this agent may reduce levels of C-reactive protein (CRP). The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.]
Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241	NCIT_C88301	[A fusion protein containing angiopoietin-2 (Ang2) and vascular endothelial growth factor (VEGF) derived peptides covalently attached, via a proprietary diketone linker, to a proprietary humanized catalytic aldolase monoclonal antibody, with potential antiangiogenic and antineoplastic activities. The Ang2/VEGF peptide moieties of Ang2/VEGF-binding peptides-antibody fusion protein CVX-241 bind to Ang2 and VEGF receptors, which may inhibit tumor angiogenesis and tumor cell proliferation. The proprietary humanized catalytic IgG1 monoclonal aldolase antibody contains reactive lysine residues in its binding sites, which react covalently with compounds having a diketone function; the Ang2 and VEGFR peptide moieties are then covalently attached to the diketone linkers via a proprietary spacer. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and play a crucial role in angiogenesis. This agent possesses an enhanced half-life compared to the naked peptides.]
Infigratinib	NCIT_C88302	[An orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.]
Pexidartinib	NCIT_C88303	[A capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity. Pexidartinib binds to and inhibits phosphorylation of stem cell factor receptor (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), which may result in the inhibition of tumor cell proliferation and down-modulation of macrophages, osteoclasts and mast cells involved in the osteolytic metastatic disease. FLT3, CSF1R and FLT3 are overexpressed or mutated in many cancer cell types and play major roles in tumor cell proliferation and metastasis.]
Tasisulam Sodium	NCIT_C88304	[The sodium salt of an acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.]
CXCR4 Antagonist BL-8040	NCIT_C88309	[An orally bioavailable inhibitor of CXC Chemokine Receptor 4 (CXCR4) with potential antineoplastic activity. CXCR4 antagonist BL-8040 selectively binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor 1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation, which may result in decreased tumor cell proliferation and migration. In addition, inhibition of CXCR4 may induce mobilization of hematopoietic cells from the bone marrow into blood. The G protein-coupled receptor CXCR4 plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; SDF-1/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.]
Allogeneic CMV/AdV-Specific Cytotoxic T Lymphocytes	NCIT_C88310	[A population of allogeneic cytotoxic T lymphocytes (CTLs) specifically reactive to cytomegalovirus (CMV) and adenovirus (AdV) with potential antiviral activity. Allogeneic CMV/AdV-specific cytotoxic T lymphocytes are prepared by exposing donor-derived CTLs to a lethally irradiated Epstein-Barr virus-positive lymphoblastoid B cell line (EBV-LCL) that has been transduced with a clinical-grade adenoviral vector (Ad5f35CMVpp65) as a source of CMV and AdV antigens. Infusion of these CTLs into stem cell transplant recipients may prevent CMV and AdV viral disease.]
Momelotinib	NCIT_C88311	[An orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.]
Cutaneous Melanoma Pathologic Primary Tumor TNM Finding v7	NCIT_C88380	[A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor. The TNM pathologic and clinical primary tumor classifications of cutaneous melanoma are the same. (from AJCC 7th Ed.)]
Cutaneous Melanoma pNX TNM Finding v7	NCIT_C88386	[Cutaneous melanoma in which the regional lymph nodes cannot be assessed (e.g., previously removed for another reason). (from AJCC 7th Ed.)]
Cutaneous Melanoma pN1a TNM Finding v7	NCIT_C88388	[Cutaneous melanoma with micrometastasis in one regional lymph node. Micrometastases are diagnosed after sentinel lymph node biopsy and completion of lymphadenectomy (if performed). (from AJCC 7th Ed.)]
Cutaneous Melanoma pTX TNM Finding v7	NCIT_C88381	[Cutaneous melanoma in which the primary tumor cannot be assessed (e.g., curettaged or severely regressed melanoma). (from AJCC 7th Ed.)]
Cutaneous Melanoma pT1 TNM Finding v7	NCIT_C88382	[Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness. (from AJCC 7th Ed.)]
Cutaneous Melanoma pT1a TNM Finding v7	NCIT_C88383	[Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness, without ulceration and with mitosis less than 1/mm2. (from AJCC 7th Ed.)]
Cutaneous Melanoma pT1b TNM Finding v7	NCIT_C88384	[Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness, with ulceration or mitoses equal to or more than 1/mm2. (from AJCC 7th Ed.)]
Facility Oncology Registry Data Standards	NCIT_C88367	[A coding manual produced by the Commission on Cancer of the American College of Surgeons that provides definitions and detailed instructions for coding patient diagnosis, treatment, and outcome.]
Breast Cancer cN2 TNM Finding v7	NCIT_C88368	[Breast cancer with metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. "Clinically detected" is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination. (from AJCC 7th Ed.)]